I want to pull the trigger on this company, but hoped that I could get some feedback from some of you gentlemen. A lot of this stuff goes over my head, and I know a lot of you guys are on top of your game, so any knowledge or opinion would be appreciated.
I just feel that FDA approval could shoot this thing right back up to 12+, with the potential for much bigger growth. Stock was up between 12 and 13 before bad news from the FDA in July, but they have another date set for possible approval, or at least positive feedback in late October.
As U.S. obesity rates near 35 percent there is markedly increased competition in the biotech industry to develop drugs and get them approved by the Food and Drug Administration. FDA approval is significantly altering profit margins for drug makers. Essentially, the farther along a drug is in drug-trials determines how much a producer will bid to buy it. Drug testing trials for obesity medications have grown more demanding since Fen-phen was pulled from the market in 1997. VIVUS Inc. which in July had to digest negative FDA feedback on its obesity drug Qnexa will be looking forward for FDA approval decision date set on October 28, 2010. The company will first have to provide more long-term safety data regarding this drug which it expects to do in the quarter of 2010. VIVUS Inc. research report is accessible for free by registering today at www.stockcall.com/VVUS100910.pdf.
Hot Forum Topics
